Moderna Says Its Vaccine Should Work Against UK and South Africa Coronavirus Variants

Illustration for article titled Moderna Says Its Vaccine Should Work Against UK and South Africa Coronavirus Variants
Photo: Paul Sancye (Getty Images)

The covid-19 vaccine developed by Moderna can likely fend off worrying variants of the coronavirus first found in the UK and South Africa, the company announced Monday. Moderna’s preliminary data appears to show that its covid-19 vaccine produces a strong immune response to these variants. However, the company still intends to work on developing a booster shot for the variant found in South Africa and others if needed.

Concern grew over these genetic variants last December, after it became clear that they were spreading widely in their respective countries. Scientists now believe that B 1.1.7, the variant in the UK, and B.1.351, the variant in South Africa, are more transmissible than previously circulating strains of the coronavirus. Since then, several countries including the U.S. have reported spotting these or similar variants spreading locally.

Because these variants contain multiple important mutations that change the virus, some scientists have worried these variants could evade the immune response of people previously infected or vaccinated. Some early data suggests that could be the case: Last week, for instance, the South African government announced finding evidence that B.1.351 could dodge existing immunity in some residents infected during the country’s first wave of the pandemic.

Advertisement

Vaccine-provided immunity isn’t necessarily the same as natural immunity, though. And there’s been some early evidence showing that vaccines may still work as intended against these variants. A study in early January found that the Pfizer vaccine worked effectively against virus strains made to carry a key mutation found in B.1.351 and B 1.1.7. However, Moderna’s data seems to be the first looking directly at whether the antibodies from vaccinated people (taken from blood samples) can neutralize these variants, as opposed to select mutations.

The results look mostly encouraging. According to Moderna, vaccinated people produced a similar level of neutralizing antibodies to B 1.1.7 as they did to earlier strains. With B.1.351, levels of neutralizing antibodies dropped sixfold, but the amount of neutralizing activity left was still deemed enough to ensure protection against illness.

“We are encouraged by these new data, which reinforce our confidence that the Moderna covid-19 vaccine should be protective against these newly detected variants,” said Moderna CEO Stéphane Bancel in a statement released by the company.

Advertisement

The findings have yet to be released to the public, though they’re expected to be posted on the preprint website bioRXiv soon. The study was carried out with the help of the U.S. federal government through the National Institutes of Health.

Advertisement

One important caveat to all this is that we don’t have a clear marker of immunity to the coronavirus in humans—what scientists call “correlates of protection.” Some mix of antibodies, T cells, and B cells specific to the virus will protect people from illness, but we don’t know the exact amounts of each needed (or if these amounts differ between different groups of people). So right now, scientists are making educated guesses about what these lab results should mean for immunity, both over the short and long-term.

Though the results could signal that neither variant will greatly threaten the effectiveness of Moderna’s vaccine (or Pfizer/BioNTech’s similar mRNA vaccine), there’s still no guarantee. And the results for B.1.351 aren’t completely reassuring. That’s likely why Moderna is moving ahead with efforts to develop a vaccine adjusted to match B.1.351 specifically; it also plans to test out whether an additional booster shot of the regular vaccine will provide further protection against these and any future variants (Two doses, taken a month apart, are the standard course). Ideally, these measures won’t be needed, but the time to work on them should be now.

Advertisement

Hurdles and challenges in vaccine development are more the rule than exception. Just today, the pharmaceutical company Merck announced it would largely abandon efforts on its two covid-19 vaccine candidates after early data suggested they wouldn’t be effective enough. Still other companies are facing shortages in mass production should their vaccines win approval.

Science writer at Gizmodo and pug aficionado elsewhere

Share This Story

Get our `newsletter`

DISCUSSION

dixie-flatline
Dixie-Flatline

I’m going to take it when it becomes available, but man...every time I read “T Cell” I get some serious Resident Evil vibes. Wish they could call it someone else.